Biotechnology Partnering Initiative – BioWindhover’s Therapeutics Area Partnering Conference
BIOTECanada and the Consulate General of Canada in Boston would like to invite you to participate in the upcoming Biotechnology Partnering Initiative, which is open to Canadian biotechnology companies and takes place in partnership with BioWindhover’s Therapeutics Area Partnering Conference http://www.tapartnerships.com/content/Main.aspx in Boston, November 17-19, 2009. The Initiative is limited to 10 Canadian biotechnology companies with therapeutic compounds in the preclinical or clinical phase of development in one or more of the following areas:
- oncology
- cardiovascular
- metabolic
- neuroscience
- inflammation/auto-immune
Canadian companies who apply to participate and are accepted will be entitled to the following benefits:
- reduced registration to the BioWindhover Conference of US$1395 (a $400 savings). This well attended Conference offers workshops, networking opportunities, panel sessions on Therapeutic Alliances and Dealmaking, and presentations by top companies in the therapeutic areas who have been chosen by BioWindhover; attendees include executives from Merck, Biogen Idec, Bristol-Myers Squibb, Millennium: The Takeda Oncology Company, GlaxoSmithKline, Novartis and Genzyme.
- one-on-one coaching in preparation for the event and for partnering meetings from professional consultants experienced in running companies, funding companies and advising biotechnology companies, and making pitches to global investors and companies;
- the arrangement of a minimum of three one-on-one meetings with venture capitalists, angels, or technology partners from Pharma, the biotechnology or medical device industry, who are based in the Boston area or attending the BioWindhover Conference. The consultant will work with you to identify the best meetings to meet your needs. If you have identified organizations of interest, the consultant can work to get you connected. Also, the consultant will make recommendations. Local venture capital firms that invest in life sciences include: MPM Healthcare, Oxford Bioscience, VIMAC, Clarus Ventures, Seaflower, among others. The Boston area is also home to corporate venture funds, including those at Novartis, Genzyme and Biogen Idec. The well connected local consulting firm has been engaged by Foreign Affairs and International Trade Canada through the Consulate General in Boston.
- participation in an invitation-only dinner on Tuesday, November 17, with venture capitalists, angels, biotechnology and pharma industry executives who would be of interest to the Canadian companies participating in the Initiative;
There is no additional charge for participation in this program; however, you must send your profile to Christine Sarkisian, Business Development Officer at the Consulate General of Canada in Boston via email by October 5, 2009. If accepted, companies must designate a specific executive from the firm who will participate in the Initiative and will communicate with the Consultant in order to ensure a productive program.
This program is being organized by the Consulate General of Canada in Boston in cooperation with BIOTECanada. It is funded by Foreign Affairs and International Trade Canada’s Technology Partnering Program and BIOTECanada.
If connecting with potential R&D partners or raising capital would benefit your company and you would like to participate in this mission, please reply promptly with your profile. You will be notified as to the status of your acceptance by October 9, 2009.
If you have any questions on this Initiative, please contact:
Christine Sarkisian
Business Development Officer
Consulate General of Canada
3 Copley Place, Suite 400
Boston, MA 02116 U.S.A.
Cell: 617-794-3197
Tel: 617-262-3760 x3360
Fax: 617-262-3415
Comments are closed.